Last reviewed · How we verify
Lianxiaxiaopi Granules
Lianxiaxiaopi Granules is a Small molecule drug developed by Tasly Pharmaceutical Group Co., Ltd. It is currently in Phase 3 development for Functional dyspepsia, Postprandial distress syndrome.
Lianxiaxiaopi Granules is a traditional Chinese medicine formulation that modulates gastrointestinal function and reduces inflammation to treat functional dyspepsia and related digestive disorders.
Lianxiaxiaopi Granules is a traditional Chinese medicine formulation that modulates gastrointestinal function and reduces inflammation to treat functional dyspepsia and related digestive disorders. Used for Functional dyspepsia, Postprandial distress syndrome.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Lianxiaxiaopi Granules |
|---|---|
| Sponsor | Tasly Pharmaceutical Group Co., Ltd |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
This herbal granule preparation combines multiple botanical ingredients traditionally used in Chinese medicine to improve gastric motility, reduce visceral hypersensitivity, and decrease inflammatory markers in the gastrointestinal tract. The formulation is designed to address the underlying pathophysiology of functional dyspepsia by enhancing digestive function and alleviating symptoms such as postprandial fullness, early satiety, and epigastric discomfort.
Approved indications
- Functional dyspepsia
- Postprandial distress syndrome
Common side effects
- Gastrointestinal upset
- Allergic reaction
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lianxiaxiaopi Granules CI brief — competitive landscape report
- Lianxiaxiaopi Granules updates RSS · CI watch RSS
- Tasly Pharmaceutical Group Co., Ltd portfolio CI
Frequently asked questions about Lianxiaxiaopi Granules
What is Lianxiaxiaopi Granules?
How does Lianxiaxiaopi Granules work?
What is Lianxiaxiaopi Granules used for?
Who makes Lianxiaxiaopi Granules?
What development phase is Lianxiaxiaopi Granules in?
What are the side effects of Lianxiaxiaopi Granules?
Related
- Manufacturer: Tasly Pharmaceutical Group Co., Ltd — full pipeline
- Therapeutic area: All drugs in Gastroenterology
- Indication: Drugs for Functional dyspepsia
- Indication: Drugs for Postprandial distress syndrome
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing